|
|
Other links at Articles > Dermatology |
| 2. |
Sorafenib Plus Dacarbazine Shows Promise in Advanced Melanoma
|
|
|
In a phase II study of chemotherapy-naive patients with stage III (unresectable) or stage IV melanoma, the addition of the Raf kinase inhibitor sorafenib to dacarbazine yielded an "encouraging" improvement in progression-free survival, the primary endpoint, and was well tolerated, researchers report. Reuters Health Information
|
| 5. |
Targeting N-Cadherin Boosts Melanoma Response to Chemotherapy
|
|
|
A novel pentapeptide -- ADH-1 -- that disrupts N-cadherin-mediated cell adhesion, enhances the response of melanoma to cytotoxic chemotherapy, according to the results of an animal study published in the May 15th issue of Cancer Research. Reuters Health Information
|
|
|
